TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02644499

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Methotrexate, a structural analogue of folic acid, can be administered orally or parenterally to treat a variety of rheumatic dise

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Methotrexate, a structural analogue of folic acid, can be administered orally or parenterally to treat a variety of rheumatic dise

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leflunomide
Description: Leflunomide inhibits pyrimidine synthesis, resulting in blockade of T-cell proliferation. Leflunomide is used in patients with moderate to severe active rheumatoid arthritis with early or late disease

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxychloroquine
Description: Hydroxychloroquine (HCQ) is a well-tolerated DMARD that is commonly used in combination therapy regimens for RA. HCQ is more commonly used than chloroquine.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone
Description: Low dose prednisolone (weeks 1-2: 15 mg/day, weeks 2-4: 10 mg/day, weeks 4-6: 5 mg/day and weeks 6-8: 2.5 mg/day then stop)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone
Description: Low dose prednisolone (weeks 1-2: 15 mg/day, weeks 2-4: 10 mg/day, weeks 4-6: 5 mg/day and weeks 6-8: 2.5 mg/day then stop)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Folic Acid
Description: Folic acid is to be given to all patients receiving methotrexate at a dose of 5 mg twice a week.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Folic Acid
Description: Folic acid is to be given to all patients receiving methotrexate at a dose of 5 mg twice a week.
Study: NCT01054885

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF Inhalation Powder
Description: Inhaled Corticosteroid (ICS)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF Inhalation Powder
Description: Inhaled Corticosteroid (ICS)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF/GW642444 Inhalation Powder
Description: Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA) for COPD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF/GW642444 Inhalation Powder
Description: Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA) for COPD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW642444 Inhalation Powder
Description: Long Acting Beta Agonist(LABA)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04433676

Intervention type: OTHER
Intervention: no intervention
Study: NCT02256280

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex
Description: Sugammadex will be diluted in a saline water solution in a 10 mL syringe.~Administration will be according to the neuromuscular blockade:~* If Post tetanic count = 1-15: 4 mg/kg~* If at least 1 twitch at the Train-of-four stimulation: 2 mg/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neostigmine
Description: Neostigmine will be diluted with atropine in a saline water solution in a 10 mL syringe.~Administration will be according to the neuromuscular blockade:~* If Post tetanic count = 1-15: 0.07 mg/kg~* If at least 1 twitch at the Train-of-four stimulation: 0.05 mg/kg Atropine will be administered at a 0.02 mg/kg dosage.
Study: NCT03599739

Intervention type: BIOLOGICAL
Intervention: Influenza
Description: Facilities will be asked to complete a survey to evaluate the impact of the influenza vaccine choice on hospitalization risk for the 2017-2018 influenza season.

Intervention type: BIOLOGICAL
Intervention: Influenza
Description: Facilities will be asked to complete a survey to evaluate the impact of the influenza vaccine choice on hospitalization risk for the 2017-2018 influenza season.
Study: NCT00938067

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Staying Connected
Description: The overarching goal of the Staying Connected intervention is to establish a compassionate and culturally sensitive treatment trajectory that diminishes posttraumatic suffering by reducing symptomatic distress, improving functional recovery, and reducing the risk of injury recurrence. This trajectory begins with surgical treatment and extends through outpatient care and community rehabilitation. The collaborative care intervention fundamentally restructures the delivery of mental health care within trauma care systems by bringing together providers currently working independently to form an interdisciplinary mental health team. Team members work together and in a liaison capacity with other trauma center providers and community practitioners in order to bridge care across service delivery sectors.
Study: NCT01432730

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefapixant
Description: Oral tablets, BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefapixant
Description: Oral tablets, BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral tablets, BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral tablets, BID
Study: NCT02534740

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tafamidis
Description: relative bioavailability

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tafamidis
Description: relative bioavailability

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tafamidis
Description: relative bioavailability

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tafamidis
Description: fasted

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tafamidis
Description: fasted

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tafamidis
Description: fed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tafamidis
Description: fed
Study: NCT04841083

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Allay Lamp
Description: The Allay Lamp is a consumer product currently available and widely used in the US. It emits low intensity (1-10 lux) narrow band (20 nm) green light (peak wavelength 520 nm) that is marketed as non-irritating to users. In that context, it is not a medical device and does not require a 510(k).
Study: NCT02668562

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Early CABG (Day 2-3 after ticagrelor discontinuation)
Description: Timing for CABG after ticagrelor discontinuation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Delayed CABG (Day 5-7 after ticagrelor discontinuation)
Description: Timing for CABG after ticagrelor discontinuation
Study: NCT00940953

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide + Azelastine
Description: nasal spray, one spray per nostril at time 0 plus one spray Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Budesonide + Azelastine
Description: nasal spray, one spray of each per nostril at time 0

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: nasal spray, one spray per nostril from each of 2 bottles at time 0
Study: NCT01536886

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 90100

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Betamethasone plus calcipotriol

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ointment vehicle

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LEO 90100 vehicle
Study: NCT04266145

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intravenous dexmedetomidine
Description: adductor-canal-blockade with 20 mL 0.25% levobupivacaine plus 1 mL normal saline while, the intravenous solution; consists of 0.5µg.kg-1 dexmedetomidine diluted in 20 mL normal saline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: adductor canal block dexmedetomidine
Description: adductor-canal-blockade with 20 mL 0.25% levobupivacaine plus 1 mL of 0.5µg.kg-1 dexmedetomidineline while, the intravenous solution;consists of 20 mL normal saline
Study: NCT01707732

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin
Description: Administration of Enoxaparin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Description: Administration of Enoxaparin
Study: NCT01515553

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: Two single doses of 0.72 mg liraglutide administered subcutaneously on two different dosing occasions separated by a wash-out period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: Two single doses of 0.72 mg liraglutide administered subcutaneously on two different dosing occasions separated by a wash-out period
Study: NCT05812872

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Toothgraft
Description: Particulate dentin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Allograft
Description: Mineralized corticocancellous allograft

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alloplast
Description: Beta tri-calcuim phosphate
Study: NCT02183649

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pentoxyverine citrate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT03729700

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Almond
Description: The almond dose will be provided as 20% of total energy (20% E) in the diet.
Study: NCT01216553

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen Therapy
Description: 1 lt/min oxygen via nasal cannulae intermittently for 30 minuets 4 times daily for 7 days

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen Therapy
Description: 1 lt/min oxygen via nasal cannulae intermittently for 30 minuets 4 times daily for 7 days
Study: NCT01038843

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: VA106483
Description: Drug: VA106483 Once daily oral dose of 1 mg VA106483 or matching placebo for 14 (+3) days. Once daily oral dose of 2 mg VA106483 or matching placebo for 14 (+3) days. Once daily oral dose of 4 mg VA106483 or matching placebo for 28 days.~Placebo: as above

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VA106483
Description: Drug: VA106483 Once daily oral dose of 1 mg VA106483 or matching placebo for 14 (+3) days. Once daily oral dose of 2 mg VA106483 or matching placebo for 14 (+3) days. Once daily oral dose of 4 mg VA106483 or matching placebo for 28 days.~Placebo: as above

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VA106483
Description: Drug: VA106483 Once daily oral dose of 1 mg VA106483 or matching placebo for 14 (+3) days. Once daily oral dose of 2 mg VA106483 or matching placebo for 14 (+3) days. Once daily oral dose of 4 mg VA106483 or matching placebo for 28 days.~Placebo: as above

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VA106483
Description: Drug: VA106483 Once daily oral dose of 1 mg VA106483 or matching placebo for 14 (+3) days. Once daily oral dose of 2 mg VA106483 or matching placebo for 14 (+3) days. Once daily oral dose of 4 mg VA106483 or matching placebo for 28 days.~Placebo: as above
Study: NCT02528981

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: Lactobacillus GR-1 and RC-14

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03236376

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: additional sensorimotor therapy for the upper limb
Description: The intervention will consist of additional physiotherapy for the upper limb after stroke consisting of sensory discrimination training and sensorimotor training.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: additional motor therapy for the upper limb after stroke
Description: The intervention will consist of additional physiotherapy for the upper limb after stroke consisting of cognitive-attention based training and motor training
Study: NCT00512213

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Immunonutrition for 5 days preoperative
Description: Impact vs Meritene

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Standard enteral nutrition for 5 days preoperative
Description: Impact vs Meritene
Study: NCT02524782

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI-4166
Description: MEDI-4166 administered subcutaneously

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered subcutaneously
Study: NCT03481595

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HealthLoop mobile application
Description: Patients will utilize the HealthLoop mobile application on their mobile device during the post-operative period in addition to standard, routine medical care.
Study: NCT01567540

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: 100 mg Sitagliptin daily for 15 weeks
Study: NCT01147510

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination of low ICS and montelukast
Description: Two puffs of Pulmicort ® turbuhaler 200µg/puff between 7 a.m. and 10 a.m and take orally a tablet of Singulair® 10mg one time per day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Monotherapy of medium dose ICS
Description: Two puffs of Pulmicort ® turbuhaler 200µg/puff between 7 a.m. and 10 a.m. and between 7 p.m. and 10 p.m. two times per day
Study: NCT02292589

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Frontal Stimulation
Description: The patient will receive anodal tDCS on left dorsolateral prefrontal cortex with an intensity of 1.5 mA for 20 minutes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Temporal Stimulation
Description: The patient will receive anodal tDCS on left temporal cortex with an intensity of 1.5 mA for 20 minutes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham Stimulation
Description: The patient will receive anodal tDCS over the occipital area for 30 seconds only and then it will be turned off without the patient's knowledge.
Study: NCT00359320

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pancreaticojejunostomy
Study: NCT01295164

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: classic aberrometer and aberrometer AOVIS-1
Description: Measurement of aberrations in early stages (1 and 2) of keratoconus as compared aberrometer AOVIS-1 with a classic aberrometer.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: classic aberrometer and aberrometer AOVIS-1
Description: Measurement of aberrations in early stages (1 and 2) of keratoconus as compared aberrometer AOVIS-1 with a classic aberrometer.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aberrometer AOVIS-I
Description: Measurement of aberrations in high stages (3 and 4) of keratoconus. Objective characterization of the optical quality of the patient eye by application of wave-front sensing technology in late stage keratoconus The complete procedure in one patient takes less than 5 minutes in only one consultation and is completely non invasive. The optical measurements only involve the use of low power infrared laser

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aberrometer AOVIS-I
Description: Measurement of aberrations in high stages (3 and 4) of keratoconus. Objective characterization of the optical quality of the patient eye by application of wave-front sensing technology in late stage keratoconus The complete procedure in one patient takes less than 5 minutes in only one consultation and is completely non invasive. The optical measurements only involve the use of low power infrared laser
Study: NCT04207788

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HIP-REP
Description: HIP-REP programme is an add on to usual care which includes 5 add on individual activity-focused interventions that will be tailored to the need of elderly with hip fracture in a liaison with the health care professionals. Home visits and follow-up phone call will be a part of programme.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: The elderly in the control group will receive usual rehabilitation. with a focus on mobilization within 24 hours postoperative as an in-patient. In the municipality physiotherapy is offered twice a week for approximately 12 weeks postoperative focusing on neuromotor control over hip, activation and strengthening of muscles as well as increase mobility. When relevant, the elderly receives a home visit by an occupational therapist who assess ADL behaviours, the use of assistive devices and the environmental hazards, preparing and adapting the home environment to prevent falls.
Study: NCT00692835

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total Thyroidectomy (Mini Video Assisted Thyroidectomy)
Description: Immediate postoperative course of patients with Thyroidectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total Thyroidectomy (Classic Thyroidectomy)
Description: Immediate postoperative course of patients with Thyroidectomy
Study: NCT01413204

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TA-7284 Low
Description: The patients will receive TA-7284-Low orally for 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TA-7284 High
Description: The patients will receive TA-7284-High orally for 24 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The patients will receive Placebo orally for 24 weeks.
Study: NCT00811915

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sirolimus
Description: Sirolimus introduction and tacrolimus withdrawal~Tacrolimus : 33 % decrease of daily dose with complete withdrawal at day 14. Sirolimus daily dose according to CYP3A5 genotype CYP3A5\*1/\*1 or \*1/\*3: 4 mg/d CYPY3A5\*3/\*3 : sirolimus 2 mg/j Adjusted to obtain a trough level between 6 and10 ng/ml

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Sirolimus introduction and tacrolimus withdrawal~Tacrolimus : 33 % decrease of daily dose with complete withdrawal at day 14. Sirolimus daily dose according to CYP3A5 genotype CYP3A5\*1/\*1 or \*1/\*3: 4 mg/d CYPY3A5\*3/\*3 : sirolimus 2 mg/j Adjusted to obtain a trough level between 6 and10 ng/ml
Study: NCT01751620

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Project ACCEPT
Description: The intervention, Project ACCEPT, combines weekly individual and group sessions that address a range of issues that impact engagement in care for youth living with HIV, including stigma, disclosure, health relationships, substance use, and future life plans.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HEALTH
Description: The comparison condition, HEALTH, matches Project ACCEPT in number of sessions and duration. The weekly sessions will cover information on alcohol, drugs, HIV and other sexually transmitted diseases (STDs) to meet the ethical responsibility to provide risk reduction information to youth assigned.
Study: NCT02497170

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Education of goal setting and achievement
Description: Education of American Association of Diabetes Educations 7 behavioral goals and how to achieve them
Study: NCT02991872

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood draw
Description: Subjects aged from ≥6 to ≤17 years at the time of enrolment in the parent clinical trial (following the CFDA post-marketing commitment requirement) and who received the full PEP rabies regimen as an intramuscular injection according to the vaccine group to which they were assigned in the V49_24 (NCT01680016) study will be invited to take part in this study. Single blood draw from subjects at Day-1/Visit-1. Subjects will be observed for 15 minutes after the blood draw.
Study: NCT00521404

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CS-1008 (humanized anti-DR5 antibody)
Description: CS-1008: 8mg/kg loading dose followed by 3mg/kg weekly.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: Gemcitabine - 1000mg/meter sq
Study: NCT02444767

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 13mg Bimatoprost Ocular Insert
Description: 13mg Bimatoprost Ocular Insert in each eye.
Study: NCT00430404

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Collaborative care (Intervention)
Description: Structured shared care with treatment protocol \& support
Study: NCT00753181

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritional Formula
Description: nutritional shake daily

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual diet
Description: usual dietary habits

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diabetes Meal Plan with experimental diabetes-specific nutritional shake, diabetes specific cereal, and diabetes specific snack bars.
Description: nutritional shake, diabetes specific cereal and diabetes snack bar daily
Study: NCT02740101

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxytocin treatment
Description: intranasal administration of oxytocin (40 IU)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo treatment
Description: intranasal administration of placebo (40 IU)
Study: NCT04424719

Intervention type: OTHER
Group type: OTHER
Intervention: Blood test
Description: High risk patients are referred for the medical oncology consultation to organize oncological surveillance after general staging of the disease. Signature of the informed consent of SALOME study, inclusion in the study and risk-adjusted surveillance schedule :~(i) Liver MRI every 6 months performed at the expert center for UM (according to guidelines).~(ii) For enucleated patients, a blood sample (3 x 6 ml EDTA tubes) is taken every 6 months according to the schedule below. Plasma and mononucleated cells will be isolated and preserved for bio-markers research.~* M0 : during the first medical oncology visit.~* At each imaging assessment, every 6 months for at least 5 years (M6 to M60) and 10 years maximum (M120).~* At the diagnosis of metastasis.~* At each significant event during the metastatic disease (surgery, treatment response or progression).
Study: NCT02607709

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lymphadenectomy in conjugation with nephroureterectomy
Description: Lymphadenectomy (intervention group only):~Lymphadenectomy performs in four fractions on the right side and two fractions on the left side according to Dissection template (Appendix 1). Renal hilar nodes are included in fraction 1 and 3, respectively.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Nephroureterectomy without lymphadenectomy
Description: Removing the kidney, ureter and bladder cuff
Study: NCT00882557

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daptomycin
Description: intradialytic: 9 mg/kg during the last 30 minutes of dialysis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daptomycin
Description: 6 mg/kg administered after a hemodialysis session